Johannes Schetelig, Professor

Department I of Internal Medicine, University Hospital Carl Gustav Carus, Dresden, Germany
Dresden, Germany

N/A

Presentation(s):

• (1554032) Bendamustine, Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Updated Results of the CLL2-BAAG Trial of the German CLL Study Group (GCLLSG)

  Sunday, October 8, 2023
  2:55 PM – 3:05 PM EDT